- Australian medicinal cannabis revenue tipped to reach $200 million in 2021 – The West Australian 06/04/2021
- 18 Minutes with Zelira Therapeutics – 180 Markets 21/12/2020
- The West Australian – Perth family describes their desperation when they sought cannabis for autistic, suicidal son 16/11/2020
- OPINION | Reform should be driving protection for medicinal cannabis patients 05/11/2020
- Investor buzz around cannabis stocks with new treatments 29/09/2020
- Zelira Therapeutics (ASX:ZLD) launches Zenivol in Australia 16/09/2020
- Zelira Therapeutics’ insomnia treatment gets TGA tick 16/09/2020
- Zelira Therapeutics launches Zenivol™ product in Australia after TGA adds to Special Access Scheme 16/09/2020
- Medicinal cannabis trial could help retired AFL players manage chronic pain 15/09/2020
- Zelira Therapeutics forms subsidiary to launch hemp-derived oral care products in the USA 08/09/2020
- Proactive – Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers 24/08/2020
- Zelira Therapeutics expands US network with Louisiana launch of HOPE products for autism sufferers 20/08/2020
- Zelira Therapeutics MD shows faith in medical cannabis strategy with placement participation 17/08/2020
- Proactive – Three medical cannabis companies in focus at Proactive’s webinar on August 11 07/08/2020
- Starts at 60 – Suffer from chronic pain? Medicinal cannabis could be the answer 16/07/2020
- TechInvest – Zelira obtains key data in cannabis dose escalation study 14/07/2020
- The Market Herald – Zelira Therapeutics (ASX:ZLD) confirms ZTL-103 is safe and well-tolerated 14/07/2020
- Proactive – Zelira Therapeutics dose escalation trial for chronic pain meets safety and efficacy endpoints 14/07/2020
- Stockhead – Pot stock Zelira Therapeutics successfully passes another Phase I clinical trial 14/07/2020
- Benzinga Article: A Medicinal Cannabis Company That’s Conducting Clinical Research On Autism, Insomnia, And More 28/05/2020